Business
Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients.
Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients..
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, March 25, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\") today announces the intent to distribute of SofPulse® investigational units to Hospital Intensive Care Units across the United States to help mitigate severe respiratory inflammation observed in some COVID-19 patients. Through Endonovo's Chief Medical Officer and consulting with our Scientific Advisory Board, we have identified a pathway for SofPulse® for the reduction of severe respiratory inflammation symptoms related to COVID-19. SofPulse® Pulsed Electromagnetic Fields Therapy (PEMF) device is FDA-cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue. Medical researchers previously working with SofPulse® in trials and clinical studies have identified an anti-inflammatory response through which SofPulse® PEMF technology may help mitigate the severe respiratory inflammation observed in some COVID-19 patients. Endonovo CEO, Alan Collier comments, “We have requested FDA emergency clearance for SofPulse® devices to be used for the treatment for severe respiratory inflammatory complications for COVID-19 patients. We believe SofPulse® PEMF technology may help to mitigate the severe respiratory inflammation observed in some COVID-19 patients much like it does in post-operative wounds, reducing morbidity and mortality and yielding faster recovery.” Endonovo is currently donating 50 investigational units to hospital Intensive Care Units treating COVID-19 patients suffering from lung inflammation symptoms. With COVID-19 being classified as a worldwide Pandemic, the Company is hopeful patients affected by this virus may be able to benefit from SofPulse® PEMF technology. COVID-19 causes a release of pro-inflammatory cytokines, which contribute to overwhelming inflammation termed a \"cytokine storm” in the respiratory system leading to worsened clinical outcomes. Clinical studies show, SofPulse® has an anti-inflammatory effect at the cellular level with no known side effects. SofPulse® has shown to reduce IL-1 Beta by 275% at the 18-hour mark after surgery. The mechanism of action is noninvasive r...